A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.

Stopped Study terminated as part of strategic considerations and not based on safety concerns.

Conditions

• Neoplasms
• Non-small-cell Lung Cancer
• Squamous Cell Carcinoma of the Head and Neck
• Renal Cell Carcinoma
• Colorectal Carcinoma
• Ovarian Carcinoma

Interventions

• DRUG: PF-07826390
• BIOLOGICAL: sasanlimab
• OTHER: SOC (anti-PD-1 + platinum -based chemo)

Sponsor

Pfizer